AbbVie's TEPKINLY Approved in Europe for Follicular Lymphoma, Offering Chemotherapy-Free Option
ABBV sits 39% above its 52-week low of $184.63 on light trading volume (0.4× avg).
Summary
The European Commission has approved AbbVie's TEPKINLY (epcoritamab) in combination with lenalidomide and rituximab for the treatment of relapsed or refractory follicular lymphoma. This marks TEPKINLY as the first and only bispecific-based therapy approved in Europe for this indication, offering a chemotherapy-free option. The approval is based on strong Phase 3 data showing a 79% reduction in the risk of disease progression or death and a 74% complete response rate. This positive regulatory news further strengthens AbbVie's oncology pipeline and follows other recent positive drug development updates.
At the time of this announcement, ABBV was trading at $256.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $453.1B. The 52-week trading range was $184.63 to $261.64. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.